Dublin, Feb. 13, 2019 (GLOBE NEWSWIRE) -- The "Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012- 2018" report has been added to ResearchAndMarkets.com's offering. The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report. The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest discovery agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all discovery stage partnering deals announced since 2012 including financial terms where available including over 3,000 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2012. In addition, a comprehensive appendix of all discovery deals since 2012 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Why do companies partner at discovery stage? 2.1. Introduction 2.2. The role of discovery stage partnering 2.2.1. In-licensing at discovery stage 2.2.2. Out-licensing at discovery stage 2.3. Difference between discovery, preclinical and clinical stage deals 2.4. Reasons for entering into discovery stage partnering deals 2.4.1. Licensors reasons for entering discovery stage deals 2.4.2. Licensees reasons for entering discovery stage deals 2.5. The future of discovery stage partnering deals Chapter 3 - Discovery stage deal strategies and structure 3.1. Introduction 3.2. At what stage do companies partner? 3.2.1. Partnering early in pharmaceutical/biotech 3.2.1.1. Discovery and preclinical stage partnering case studies 3.2.1.1.a. Case study: LEO Pharma - 4SC 3.2.1.1.b. Case study: Heptares Therapeutics - Cubist 3.2.1.1.c. Case study: Incyte - Agenus Bio 3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec 3.2.2. Partnering later in pharmaceutical/biotech 3.2.2.1. Clinical stage partnering case studies 3.2.2.1.a. Case study: Servier - GeNeuro 3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals 3.2.2.1.c. Case study: AstraZeneca - Ardelyx 3.2.2.1.d. Case study: Baxter - Onconova Therapeutics 3.3. Early and later stage partnering - a risk/cost comparison 3.4. What do companies spend on discovery, preclinical and clinical stage partnering? 3.5. Pure versus multi-component partnering deals 3.6. Pure licensing agreement structure 3.6.1. Example pure licensing agreements 3.6.1.a. Case study : Pfizer - Spark Therapeutics 3.6.1.b. Case study : Contrafect - Trellis Bioscience 3.7. Multicomponent discovery stage partnering agreements 3.7.1.a. Example multicomponent early stage clauses 3.7.1.a. Case study: Tracon - Boehringer Ingelheim - Macrogenics 3.7.1.b. Case study: Fibrocell Science - Intrexon Chapter 4 - Discovery stage partnering payment strategies 4.1. Introduction 4.2. Discovery stage payment strategies 4.3. Payment options 4.3.1. Headline values 4.3.2. Upfront payments 4.3.2.1. Conditionality of upfront payments 4.3.3. Loans 4.3.4. Convertible loans 4.3.5. Equity 4.3.6. R&D funding 4.3.7. Licensing fees 4.3.8. Milestone payments 4.3.9. Royalty payments 4.3.9.1. Issues affecting royalty rates 4.3.9.2. Royalties on combination products 4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech 4.3.9.3. Guaranteed minimum/maximum annual payments 4.3.9.4. Royalty stacking 4.3.9.5. Royalties and supply/purchase contracts 4.3.10. Quids 4.3.11. Option payments Chapter 5 - Trends in discovery stage deal making 5.1. Introduction 5.2. Discovery stage partnering over the years 5.2.1. Attributes of discovery deals 5.3. Discovery stage partnering by deal type 5.4. Discovery stage partnering by disease type 5.5. Partnering by discovery stage technology type 5.6. Discovery stage partnering by most active company since 2012 Chapter 6 - Payment terms for discovery stage partnering 6.1. Introduction 6.2. Guidelines for discovery stage payment terms 6.2.1. Upfront payments 6.2.2. Milestone payments 6.2.3. Royalty payments 6.3. Discovery stage payment terms - deal data analysis 6.3.1. Public data 6.3.2. Survey data 6.4. Payment terms analysis 6.4.1. Discovery stage headline values 6.4.2. Discovery stage deal upfront payments 6.4.3. Discovery stage deal milestone payments 6.4.4. Discovery stage royalty rates Chapter 7 - Leading discovery stage deals 7.1. Introduction 7.2. Top discovery stage deals by value Chapter 8 - Top 50 most active discovery stage dealmakers 8.1. Introduction 8.2. Top 50 most active discovery stage dealmakers Chapter 9 - Discovery stage partnering contracts directory 9.1. Introduction 9.2. Discovery stage deals with contracts 2012 to 2018 Chapter 10 - Discovery stage deal making by development stage 10.1. Introduction 10.2. Deals by discovery stage Appendices Appendix 1 - Discovery stage dealmaking by companies A-Z Appendix 2 - Discovery stage dealmaking by industry sector Appendix 3 - Discovery stage dealmaking by stage of development Appendix 4 - Discovery stage dealmaking by therapy area Appendix 5 - Discovery stage dealmaking by technology type For more information about this report visit https://www.researchandmarkets.com/research/x...a_and?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Biotechnology, Pharmaceuticals, Drug Discovery
